Curated News
By: NewsRamp Editorial Staff
March 11, 2026

BioCorRx Secures U.S. Patent for Biodegradable Naltrexone Implant Technology

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • BioCorRx's new U.S. patent strengthens its intellectual property portfolio for biodegradable naltrexone implants, giving it a competitive edge in addiction treatment and weight management markets.
  • The patent covers a biodegradable implant technology that provides controlled delivery of naltrexone, with clinical studies ongoing through BioCorRx Pharmaceuticals to advance development.
  • This technology could improve treatment for substance abuse disorders and weight management, potentially helping millions affected by addiction and obesity lead healthier lives.
  • BioCorRx's biodegradable naltrexone implant represents innovative pharmaceutical technology, with patents extending to weight management applications when combined with behavioral counseling.

Impact - Why it Matters

This development matters because it represents a significant advancement in addiction treatment and weight management technologies, addressing pressing public health crises. With opioid and methamphetamine use disorders affecting millions in the U.S., and obesity rates rising globally, BioCorRx's biodegradable naltrexone implant offers a promising solution for controlled, long-term medication delivery. This could improve patient adherence and outcomes by reducing the need for frequent dosing, potentially lowering relapse rates in substance abuse and enhancing weight loss efforts. The patent strengthens the company's intellectual property, fostering innovation and investment in treatments that tackle complex health challenges, ultimately benefiting individuals and healthcare systems by providing more effective, sustainable options for managing these disorders.

Summary

BioCorRx Inc. (OTC: BICX), a developer of innovative treatment programs for substance abuse and related disorders, has achieved a significant milestone with the issuance of U.S. Patent No. 12,569,430 for its "Biodegradable Implant Including Naltrexone" technology. This patent strengthens the company's growing intellectual property portfolio focused on implant-based naltrexone delivery systems, which are designed to provide controlled release of the medication. The announcement was made via a press release distributed through NEWMEDIAWIRE, highlighting the company's ongoing commitment to advancing pharmaceutical solutions for addiction and weight management.

The newly issued patent is part of BioCorRx's broader strategy, which includes international patents covering additional therapeutic applications. Notably, the company holds an Israeli patent for using naltrexone implants in weight management programs when combined with behavioral or nutritional counseling. BioCorRx continues to pursue further patent protection in the United States and internationally, underscoring its dedication to expanding its portfolio. Development of these technologies is primarily advanced through BioCorRx Pharmaceuticals Inc., a majority-owned subsidiary, with clinical studies underway, including one that commenced in January 2026 and is supported by the National Institute on Drug Abuse (NIDA).

BioCorRx's comprehensive approach includes the Beat Addiction Recovery program, which combines proprietary Cognitive Behavioral Therapy modules with peer support via a mobile app, and the UnCraveRx® Weight Loss Program, offering concierge wellness services. For more details on UnCraveRx®, visit www.uncraverx.com. The company also commercializes LUCEMYRA® (lofexidine), an FDA-approved medication for mitigating opioid withdrawal symptoms, and is developing BICX104, an investigational biodegradable naltrexone implant. Additional information on these initiatives can be found at www.BioCorRx.com. This news underscores BioCorRx's role in addressing critical public health issues like Methamphetamine Use Disorder (MUD), Opioid Use Disorder (OUD), and obesity, with naltrexone serving as a key therapeutic agent due to its opioid receptor antagonism properties.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BioCorRx Secures U.S. Patent for Biodegradable Naltrexone Implant Technology

blockchain registration record for this content.